- Home
- CLDX vs AGIO Comparison
CLDX vs AGIO Comparison
Compare CLDX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- AGIO
- Stock Information
- Founded
- CLDX N/A
- AGIO 2007
- Country
- CLDX United States
- AGIO United States
- Employees
- CLDX N/A
- AGIO N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- AGIO Health Care
- Exchange
- CLDX Nasdaq
- AGIO Nasdaq
- Market Cap
- CLDX 1.3B
- AGIO 1.4B
- IPO Year
- CLDX 2008
- AGIO 2013
- Fundamental
- Price
- CLDX $23.36
- AGIO $39.23
- Analyst Decision
- CLDX Buy
- AGIO Buy
- Analyst Count
- CLDX 9
- AGIO 6
- Target Price
- CLDX $50.00
- AGIO $58.60
- AVG Volume (30 Days)
- CLDX 1.1M
- AGIO 615.0K
- Earning Date
- CLDX 08-07-2025
- AGIO 07-31-2025
- Dividend Yield
- CLDX N/A
- AGIO N/A
- EPS Growth
- CLDX N/A
- AGIO N/A
- EPS
- CLDX N/A
- AGIO 11.45
- Revenue
- CLDX $7,559,000.00
- AGIO $37,035,000.00
- Revenue This Year
- CLDX N/A
- AGIO $22.30
- Revenue Next Year
- CLDX N/A
- AGIO $219.19
- P/E Ratio
- CLDX N/A
- AGIO $3.39
- Revenue Growth
- CLDX 24.49
- AGIO 25.96
- 52 Week Low
- CLDX $14.40
- AGIO $23.42
- 52 Week High
- CLDX $47.00
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CLDX 64.61
- AGIO 70.51
- Support Level
- CLDX $20.76
- AGIO $34.60
- Resistance Level
- CLDX $23.55
- AGIO $40.06
- Average True Range (ATR)
- CLDX 1.22
- AGIO 1.45
- MACD
- CLDX 0.20
- AGIO 0.43
- Stochastic Oscillator
- CLDX 95.29
- AGIO 88.98
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.